RxDoctor Payments Data

Christina Bauer, MD

Gastroenterology · Greenville, SCNPI 1912342742

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (49.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Pfizer at 51.5% of the total. Among gastroenterology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$178,757in general payments, 2019–2025

Across 202 payments — averaging $884.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$92K
  • AbbVie$85K
  • Johnson & Johnson$887
  • Takeda Pharmaceuticals U.S.A., Inc.$261
  • Janssen Scientific Affairs, LLC$173
  • Sanofi$140
  • plus $524 from 12 others

What the payments were for

  • Speaking & faculty fees$72,87541%
  • Grants$88,95350%
  • Travel & lodging$11,4276%
  • Food & beverage$5,4873%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,757 in reported general payments places this provider in the 95th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,803
Medicare patients
287
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide17$12,309
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates34$2,304
Colestipol Hcl11$794
Omeprazole60$610
Codeine Sulfate11$438
Mercaptopurine12$420
Sucralfate28$405
Pantoprazole Sodium26$272
Sulfasalazine12$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$84,663$12,30917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →